Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $136.00 Price Target at Wells Fargo & Company

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its target price dropped by Wells Fargo & Company from $145.00 to $136.00 in a research note issued on Friday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective would suggest a potential upside of 47.07% from the company’s previous close.

A number of other research analysts have also commented on RYTM. Guggenheim lifted their price objective on shares of Rhythm Pharmaceuticals from $140.00 to $143.00 and gave the company a “buy” rating in a research note on Friday. Canaccord Genuity Group upped their price target on shares of Rhythm Pharmaceuticals from $114.00 to $141.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research note on Thursday, January 22nd. HC Wainwright upped their price target on shares of Rhythm Pharmaceuticals from $123.00 to $125.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. Finally, Citizens Jmp raised their price objective on shares of Rhythm Pharmaceuticals from $167.00 to $176.00 and gave the stock a “market outperform” rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $133.71.

Rhythm Pharmaceuticals Stock Performance

NASDAQ RYTM traded down $5.60 during trading on Friday, reaching $92.47. 313,298 shares of the company’s stock were exchanged, compared to its average volume of 650,791. The company has a 50 day moving average price of $104.28 and a two-hundred day moving average price of $103.50. The stock has a market cap of $6.17 billion, a P/E ratio of -29.95 and a beta of 2.00. Rhythm Pharmaceuticals has a 1 year low of $45.90 and a 1 year high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.06. The firm had revenue of $57.25 million during the quarter, compared to analysts’ expectations of $56.16 million. Rhythm Pharmaceuticals had a negative net margin of 110.32% and a negative return on equity of 433.21%. Rhythm Pharmaceuticals’s quarterly revenue was up 36.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.72) earnings per share. Research analysts forecast that Rhythm Pharmaceuticals will post -4.32 EPS for the current fiscal year.

Insider Activity at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, insider Pamela J. Cramer sold 3,350 shares of the business’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $111.00, for a total value of $371,850.00. Following the completion of the transaction, the insider directly owned 20,814 shares in the company, valued at approximately $2,310,354. The trade was a 13.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Hunter C. Smith sold 4,385 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total value of $444,025.10. Following the sale, the chief financial officer owned 110,512 shares in the company, valued at $11,190,445.12. This trade represents a 3.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 25,003 shares of company stock valued at $2,589,015 over the last ninety days. 6.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Xponance LLC increased its position in Rhythm Pharmaceuticals by 2.6% during the fourth quarter. Xponance LLC now owns 4,269 shares of the company’s stock worth $457,000 after purchasing an additional 107 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Rhythm Pharmaceuticals by 4.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,568 shares of the company’s stock worth $259,000 after purchasing an additional 110 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Rhythm Pharmaceuticals by 39.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 399 shares of the company’s stock worth $43,000 after buying an additional 113 shares during the period. Captrust Financial Advisors grew its stake in shares of Rhythm Pharmaceuticals by 0.7% in the second quarter. Captrust Financial Advisors now owns 17,471 shares of the company’s stock valued at $1,104,000 after buying an additional 114 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Rhythm Pharmaceuticals by 48.6% during the 4th quarter. GAMMA Investing LLC now owns 361 shares of the company’s stock valued at $39,000 after buying an additional 118 shares during the period.

Rhythm Pharmaceuticals News Summary

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Analysts at Citizens Jmp raised their price target to $176 and kept a “market outperform” rating, implying a large upside vs. current levels. Article Title
• Positive Sentiment: Guggenheim nudged its target up to $143 with a “buy” rating, another bullish signal from the sell‑side. Article Title
• Positive Sentiment: Q4 results: EPS of ($0.73) beat consensus ($0.79) and revenue of $57.25M topped estimates; revenue rose ~37% year‑over‑year — evidence of commercial traction for IMCIVREE/setmelanotide. Press Release
• Positive Sentiment: Near‑term clinical and regulatory catalysts: PDUFA goal date for the sNDA in acquired hypothalamic obesity is March 20, 2026, and topline Phase 3/Phase 2 readouts (EMANATE and Japanese cohort) are due in March — binary events that could materially re‑rate the stock. Company Release
• Neutral Sentiment: Full Q4 earnings call transcript and coverage are available for investors wanting color on commercial uptake, launch plans and upcoming milestones. Earnings Transcript
• Negative Sentiment: Needham reduced its price target (from $148 to $139) despite keeping a “buy” rating — mixed analyst signals can create short‑term selling pressure. Ticker Report
• Negative Sentiment: Management flagged significantly higher 2026 non‑GAAP operating expenses ($385M–$415M) as HO launch preparations accelerate — investors may view this as margin dilution and a cash‑burn risk ahead of broader commercialization. Seeking Alpha
• Negative Sentiment: Company still shows a negative net margin and very negative ROE — structural profitability concerns remain until revenue scales and launch economics improve. MarketBeat

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.